|
1
|
Bevis KS, McNally LR, Sellers JC, Della
Manna D, Londono Joshi A, Amm H, Straughn JM Jr and Buchsbaum DJ:
Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in
combination with taxane/platinum-based chemotherapy in an ovarian
cancer model. Gynecol Oncol. 121:193–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Estes JM, Oliver PG, Straughn JM Jr, Zhou
T, Wang W, Grizzle WE, Alvarez RD, Stockard CR, LoBuglio AF and
Buchsbaum DJ: Efficacy of anti-death receptor 5 (DR5) antibody
(TRA-8) against primary human ovarian carcinoma using a novel ex
vivo tissue slice model. Gynecol Oncol. 105:291–298. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buchsbaum DJ, Forero-Torres A and LoBuglio
AF: TRAIL-receptor antibodies as a potential cancer treatment.
Future Oncol. 3:405–409. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du YW, Chen JG, Bai HL, Huang HY, Wang J,
Li SL, Liu GC, Jiang Q, Chai J, Zhao YP and Ma YF: A novel
agonistic anti-human death receptor 5 monoclonal antibody with
tumoricidal activity induces caspase- and mitochondrial-dependent
apoptosis in human leukemia Jurkat cells. Cancer Biother
Radiopharm. 26:143–152. 2011. View Article : Google Scholar
|
|
5
|
Du YW, Liu GC, Wang J, Zhao YP, Li SL,
Chen JG, Jiang Q, Cai J and Ma YF: Caspase-dependent molecular
mechanisms of anti-human DR5 monoclonal antibody mDRA-6 inducing
apoptosis of human leukemia Jurkat cells. Ai Zheng. 28:112–116.
2009.PubMed/NCBI
|
|
6
|
Wu XX and Kakehi Y: Enhancement of
lexatumumab-induced apoptosis in human solid cancer cells by
Cisplatin in caspase-dependent manner. Clin Cancer Res.
15:2039–2047. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang J, Lin Z, Qiao CX, Lv M, Yu M, Xiao
H, Wang Q, Wang L, Feng J, Shen B, Ma Y and Li Y: Characterization
of a novel anti-DR5 monoclonal antibody WD1 with the potential to
induce tumor cell apoptosis. Cell Mol Immunol. 5:55–60. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang YG, Zhao KP, Chen JG, Zhang JY, Yu M,
Li Y and Shen BF: The characteristic of an anti-human DR5 antibody
A6. Cell Mol Immunol. 5:183–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yagita H, Takeda K, Hayakawa Y, Smyth MJ
and Okumura K: TRAIL and its receptors as targets for cancer
therapy. Cancer Sci. 95:777–783. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Y, Chen C, Zheng Y, Zhang J, Tao X,
Liu S, Zheng D and Liu Y: A novel anti-human DR5 monoclonal
antibody with tumoricidal activity induces caspase-dependent and
caspase-independent cell death. J Biol Chem. 280:41940–41952. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li W, Wang S, Chen C and Zhuang G:
Induction of tumor cell apoptosis via Fas/DR5. Cell Mol Immunol.
3:467–471. 2006.PubMed/NCBI
|
|
12
|
Kang Z, Chen JJ, Yu Y, Li B, Sun SY, Zhang
B and Cao L: Drozitumab, a human antibody to death receptor 5, has
potent antitumor activity against rhabdomyosarcoma with the
expression of caspase-8 predictive of response. Clin Cancer Res.
17:3181–3192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yada A, Yazawa M, Ishida S, Yoshida H,
Ichikawa K, Kurakata S and Fujiwara K: A novel humanized anti-human
death receptor 5 antibody CS-1008 induces apoptosis in tumor cells
without toxicity in hepatocytes. Ann Oncol. 19:1060–1067. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin H, Yang R, Ross J, Fong S, Carano R,
Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, Schwall R and
Ashkenazi A: Cooperation of the agonistic DR5 antibody apomab with
chemotherapy to inhibit orthotopic lung tumor growth and improve
survival. Clin Cancer Res. 14:7733–7740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duiker EW, Mom CH, de Jong S, Willemse PH,
Gietema JA, van der Zee AG and de Vries EG: The clinical trail of
TRAIL. Eur J Cancer. 42:2233–2240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Camidge DR: Apomab: an agonist monoclonal
antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use
in the treatment of solid tumors. Expert Opin Biol Ther.
8:1167–1176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu YJ, Ma YF, Zhang J, Zhao YP, Bai HL
and Li SL: Synergistic lethal effect of mDRA-6 and nimesulide on
human hepatocellular cancer cell line SMMC-7721. Ai Zheng.
27:374–378. 2008.PubMed/NCBI
|
|
18
|
Li SL, Ma YF, Liu GC, Zhang J, Bai HL, Liu
YJ and Lu F: Adriamycin enhances anti-human DR5 monoclonal antibody
(mDRA-6) induced HL-60 cells apoptosis. Zhonghua Xue Ye Xue Za Zhi.
27:461–464. 2006.PubMed/NCBI
|
|
19
|
Ding B, Wu X, Fan W, Wu Z, Gao J, Zhang W,
Ma L, Xiang W, Zhu Q, Liu J, Ding X and Gao S: Anti-DR5 monoclonal
antibody-mediated DTIC-loaded nanoparticles combining chemotherapy
and immunotherapy for malignant melanoma: target formulation
development and in vitro anticancer activity. Int J Nanomedicine.
6:1991–2005. 2011.
|
|
20
|
Kendrick JE, Straughn JM Jr, Oliver PG,
Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD and Buchsbaum
DJ: Anti-tumor activity of the TRA-8 anti-DR5 antibody in
combination with cisplatin in an ex vivo human cervical cancer
model. Gynecol Oncol. 108:591–597. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Straughn JM Jr, Oliver PG, Zhou T, Wang W,
Alvarez RD, Grizzle WE and Buchsbaum DJ: Anti-tumor activity of
TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in
combination with chemotherapy and radiation therapy in a cervical
cancer model. Gynecol Oncol. 101:46–54. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rajeshkumar NV, Rasheed ZA, Garcia-Garcia
E, Lopez-Rios F, Fujiwara K, Matsui WH and Hidalgo M: A combination
of DR5 agonistic monoclonal antibody with gemcitabine targets
pancreatic cancer stem cells and results in long-term disease
control in human pancreatic cancer model. Mol Cancer Ther.
9:2582–2592. 2010. View Article : Google Scholar
|
